Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 3:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Pediatric Epilepsy
Interventions
Depakote Delayed-Release/Depakote Sprinkle, Depakote ER
Drug
Lead sponsor
Abbott
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Cytarabine, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Pharmacological Study
Drug · Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Conditions
Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Conditions
Asthma in Children
Interventions
Comparator 1 (tailored approach), Comparator 2 (insecticidal bait)
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
5 Years to 17 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Autism Spectrum Disorder, Autism
Interventions
Fecal Microbiota Transplant; Vancomycin
Biological
Lead sponsor
ProgenaBiome
Other
Eligibility
2 Years and older
U.S. locations
1
States / cities
Ventura, California
Conditions
Plaque Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 26 more
Conditions
Neoplasm Metastasis
Interventions
Olaratumab, Doxorubicin, Vincristine, Irinotecan, Ifosfamide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Up to 17 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
Conditions
Appendicitis
Interventions
laparoscopic appendectomy, open appendectomy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Up to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Portland, Oregon
Conditions
Autistic Disorder
Interventions
Placebo, RO5028442
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Los Ageles, California • New Haven, Connecticut • The Bronx, New York
Conditions
Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer, Pediatric Brain Tumor, Diffuse Glioma
Interventions
Marizomib, Panobinostat
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Neurofibromatosis Type 1
Interventions
Selumetinib granule formulation, Selumetinib capsule formulation
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Examining the Effectiveness of My Scrivener on Handwriting Legibility

NCT00693303
Conditions
Healthy Children
Interventions
Handwriting Training using My Scrivener
Behavioral
Lead sponsor
Shenandoah University
Other
Eligibility
5 Years to 13 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Winchester, Virginia
Conditions
Hereditary Angioedema (HAE)
Interventions
CINRYZE 500, CINRYZE 1000
Biological
Lead sponsor
Shire
Industry
Eligibility
6 Years to 11 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Colorado Springs, Colorado • Las Vegas, Nevada • Eugene, Oregon
Conditions
Sleep Apnea, Sleep Apnea Syndromes in Children, Sleep Apnea Syndromes
Interventions
Medical Device: Wesper Lab Home Sleep Test
Device
Lead sponsor
Wesper Inc
Industry
Eligibility
2 Years to 21 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Edmond, Oklahoma
Conditions
Healthy Volunteers
Interventions
BMS-986419 DR Capsule, BMS-986419 IR Tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Conditions
Chronic Diseases in Children
Interventions
Comprehensive care (CC) program, Enhanced telemedicine (ETM)
Other · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 18 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV cps2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Conditions
Gram Positive Bacterial Infection
Interventions
Daptomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
3 Months to 24 Months
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 5 more
Conditions
Rhinitis
Interventions
phenylephrine HCl
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Cypress, California
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Conditions
Medulloblastoma
Interventions
LDE225, TMZ
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
4 Months and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 5 more
Completed Phase 2 Interventional Results available

Oral Rivaroxaban in Children With Venous Thrombosis

NCT01684423
Conditions
Venous Thrombosis
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Active comparator, Rivaroxaban (BAY59-7939) suspension
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more
Conditions
Allergic Rhinitis
Interventions
diphenhydramine HCl
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Little Rock, Arkansas